Core Viewpoint - The analysis of five randomized controlled trials from the STEP program indicates that adults treated with semaglutide for obesity are more likely to reduce or stop the use of antihypertensive and lipid-lowering medications compared to those receiving a placebo [4][6][9]. Group 1: Study Findings - Semaglutide, a GLP-1 receptor agonist, is associated with significant weight loss and improvements in various metabolic parameters, leading to a reduction in the need for antihypertensive and lipid-lowering medications [6][12]. - Participants receiving 2.4 mg of semaglutide showed a higher proportion of reduced or stopped antihypertensive or lipid-lowering treatment compared to the placebo group at the end of the treatment [9][10]. - In the analysis, semaglutide-treated participants experienced a greater weight reduction, which correlated with decreased medication needs for hypertension and dyslipidemia [10][12]. Group 2: Specific Data on Antihypertensive and Lipid-Lowering Medications - Among obese adults without diabetes, 17.7% in the semaglutide group stopped antihypertensive medications at 68 weeks, compared to 9% in the placebo group [14]. - In the same group, 16.5% of semaglutide users reduced their antihypertensive treatment intensity, while only 4.8% in the placebo group did so [14]. - For obese adults with type 2 diabetes, 9.8% in the semaglutide group stopped antihypertensive medications, compared to 7.3% in the placebo group [16]. Group 3: Lipid-Lowering Medication Insights - In obese adults without diabetes, 10.1% in the semaglutide group stopped lipid-lowering treatment at 68 weeks, while 4.5% in the placebo group did the same [17]. - The proportion of participants reducing lipid-lowering treatment intensity was similar between groups, with 4% in the semaglutide group and 3.9% in the placebo group [17]. - In the group of obese adults with type 2 diabetes, 10.1% in the semaglutide group stopped lipid-lowering treatment, compared to 5.4% in the placebo group [17]. Group 4: Blood Pressure Relief - Among obese adults without diabetes, 13.7% of those treated with semaglutide achieved hypertension relief at 68 weeks, compared to 6.2% in the placebo group [19]. - In the analysis of obese adults with type 2 diabetes, 5.7% of semaglutide-treated individuals experienced hypertension relief, while 3.4% in the placebo group did [19]. - The findings suggest that significant weight loss can lead to reduced or discontinued use of antihypertensive medications due to improved blood pressure control [19].